Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
5.01
0.00 (0.00%)
Jan 17, 2025, 4:00 PM EST - Market closed
Annovis Bio Employees
As of December 31, 2023, Annovis Bio had 16 total employees, including 6 full-time and 10 part-time employees. The number of employees increased by 11 or 220.00% compared to the previous year.
Employees
16
Change (1Y)
11
Growth (1Y)
220.00%
Revenue / Employee
n/a
Profits / Employee
-$2,558,694
Market Cap
69.12M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
ANVS News
- 6 days ago - Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection - GlobeNewsWire
- 6 weeks ago - Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace - GlobeNewsWire
- 6 weeks ago - /C O R R E C T I O N -- Today's Marketplace/ - PRNewsWire
- 2 months ago - Annovis to Host Year-End Investor Webcast on December 11, 2024 - GlobeNewsWire
- 2 months ago - IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio - GlobeNewsWire
- 3 months ago - FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs - GlobeNewsWire
- 3 months ago - Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases - GlobeNewsWire
- 3 months ago - Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations - GlobeNewsWire